News
Investors have been keeping a sharp eye on Bristol Myers as its stock has lagged behind peers recently. Bristol Myers’ stock ...
Bristol-Myers Squibb is testing MORAb-202 in a Phase 2 trial to challenge traditional chemotherapy for platinum-resistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback